New cancer drug IPH4502 enters first human tests
NCT ID NCT06781983
First seen Jan 08, 2026 · Last updated Jun 22, 2026 · Updated 25 times
Summary
This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will also look for early signs that it might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Léon Bérard
RECRUITINGLyon, 69008, France
Contact
-
Gustave Roussy Cancer Institute
RECRUITINGVillejuif, 94805, France
Contact
-
John Theurer Cancer Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact
-
Massachusetts General Hospital - Boston
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
-
Mount Sinai Tisch Cancer Center
RECRUITINGNew York, New York, 10029, United States
Contact
-
NEXT Oncology - Dallas
RECRUITINGDallas, Texas, 75039, United States
Contact
-
NEXT Oncology - Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IPH4502 (a drug that targets Nectin-4, a protein on some cancer cells)
What this could lead to
If this early trial shows safety and hints of tumor shrinkage, it could lead to a new treatment option for people with advanced cancers that have Nectin-4.
What could go wrong
This is a very early, first-in-human Phase 1 trial with only 145 participants. The drug may not be safe or effective, and side effects are unknown. Many early cancer drugs do not advance.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.